Open science, open access and open source software at Open Medicine

作者: Alper Çelik , I. Ebru Arabacı , Unal Erkorkmaz , Suat Kutun , Sabahattin Aslan

DOI: 10.2478/S11536-007-0006-6

关键词:

摘要: We aimed to investigate the correlation between quantitative CerbB-2 expressions with conventional prognostic factors, and distinct nodal involvement in patients invasive breast carcinoma. One hundred fifty seven consecutive carcinoma were retrospectively analysed. Level I–II, III, Rotter (Interpectoral) group lymph nodes separately examined recorded. For each patient estrogen receptor (ER), progesteron (PR), CerbB-2, P53 status defined using immunohistochemistry. Age, tumor localisation, menopausal status, grade presence of intraductal component also expression did not correlate age, localisation status. There was a reverse, but weak size (p=0.034). In subgroup analysis positive cases, magnitude positivity (p=0.551). univariate I-II, Rotter. linearly increased number this difference significant (p=0,039). III metastases (p=0.005). But among (p=0.82). P53, PR differ according oncogene expression. detected reverse ER (p=0.011). It is concluded that CerbB2 increases I–II axillary nodes, ER. Also, more common node metastases.

参考文章(44)
James S. Huston, Andrew J.T. George, Engineered antibodies take center stage Human antibodies. ,vol. 10, pp. 127- 142 ,(2001) , 10.3233/HAB-2001-103-405
Mårten Fernö, Åke Borg, Bo Baldetorp, Dick Killander, Håkan Olsson, H Sigurdsson, ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene. ,vol. 6, pp. 137- 143 ,(1991)
Donald P. McDonnell, D. Craig Allred, Zafar Nawaz, William L. McGuire, Bert W. O'Malley, Geoffrey L. Greene, Suzanne A. W. Fuqua, Saundra D. Fitzgerald, Richard M. Elledge, Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Research. ,vol. 52, pp. 483- 486 ,(1992)
Susanne H. Estourgie, Omgo E. Nieweg, Renato A. Valdés Olmos, Emiel J. Th. Rutgers, Bin B. R. Kroon, Lymphatic drainage patterns from the breast. Annals of Surgery. ,vol. 239, pp. 232- 237 ,(2004) , 10.1097/01.SLA.0000109156.26378.90
C LOHRISCH, An overview of HER2. Seminars in Oncology. ,vol. 28, pp. 3- 11 ,(2001) , 10.1016/S0093-7754(01)90103-4
LYDIA L. NAKOPOULOU, ANASTASIA ALEXIADOU, GEORGE E. THEODOROPOULOS, ANDREAS CH. LAZARIS, ANASTASIA TZONOU, ANDONIS KERAMOPOULOS, Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. The Journal of Pathology. ,vol. 179, pp. 31- 38 ,(1996) , 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O
A Jukkola, R Bloigu, Y Soini, E.-R Savolainen, K Holli, G Blanco, c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. European Journal of Cancer. ,vol. 37, pp. 347- 354 ,(2001) , 10.1016/S0959-8049(00)00395-6
D. Kennedy, Responding to fraud. Science. ,vol. 314, pp. 1353- 1353 ,(2006) , 10.1126/SCIENCE.1137840
N.J. Bundred, Prognostic and predictive factors in breast cancer. Cancer Treatment Reviews. ,vol. 27, pp. 137- 142 ,(2001) , 10.1053/CTRV.2000.0207